6) siRNA knockdown or gene silencing identified BRD4 as a potential target to treat a variety of diseases, such as leukemia (Zuber et al., 2011), heart failure (Anand et al., 2013), ovarian carcinoma (Baratta et al., 2015), prostate cancer (Asangani et al., 2014), and pulmonary disease (Khan et al., 2014). This evidence concerns the gene BRD4 and Familial prostate cancer.